The latest episode of the hugely popular Movers & Shakers podcast features our very own Will Cook, CEO of Cure Parkinson’s.

This episode, which also features University College London’s Professor Tom Foltynie, looks at the progress of ongoing clinical work in the world of Parkinson’s research including the phase 3 clinical trials of exenatide (the Bydureon trial) and ambroxol (the ASPro-PD trial).

Will also discusses the origins of Cure Parkinson’s, including his close friendship with our late founder Tom Isaacs, and even gets a bit of a trademark grilling from Jeremy Paxman too!

Will and Tom with the Movers & Shakers

The Movers & Shakers are a group of six friends, including some familiar faces, all living with Parkinson’s who created a podcast to start an honest and informative conversation about the condition. The group is made up of Cure Parkinson’s Patron and Vicar of Dibley co-writer Paul Mayhew-Archer; former BBC presenter and legendary inquisitor Jeremy Paxman; former BBC technology correspondent Rory Cellan-Jones; High Court Judge Sir Nicholas Mostyn; former BBC political expert Mark Mardell and former ‘Working Lunch’ presenter, management consultant and lecturer Gillian Lacey-Solymar.

Listen to the episode below.

How helpful was this content?

/ 5. Vote count:

We are sorry that this content was not useful for you

Let us improve this content

Can you tell us how we can improve this content?